Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study

Figure 1 Study enrollment process. TGN: Thioguanine nucleotides.

Figure 2 Histograms demonstrates the distribution of vedolizumab serum trough concentrations. A: At week 0; B: At week 48; C: Scatter plot illustrates the relationship between vedolizumab serum trough concentrations at week 0 and week 48, categorized by thiopurine use.

Figure 3 Association of vedolizumab serum trough concentrations (µg/mL) with clinical remission. A: Concentration at week 0 vs clinical remission at week 48; B: Concentration at week 48 vs clinical remission at week 48; C: Concentration at week 48 vs clinical remission at 2 years.

Figure 4 Longitudinal association between vedolizumab serum trough concentrations at 3 distinct time points. A: Clinical; B: Endoscopy; C: Histology; D: Histo-endoscopic outcomes over 48 weeks.

Figure 5 Remission rates expressed per quartile. A: At week 0; B: At week 48.